

The Board:

1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B33/ER18 (collectively, "Table 1");
2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Approves the additional funding for the Zimbabwe HIV Program and its resultant total program budget, as listed in Table 1c of Section IV to GF/B33/ER18;
4. Approves the reinvestment of within-allocation efficiencies for the Bangladesh malaria and Cote d'Ivoire malaria grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER18;
5. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1a: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Countries)

N	Country	Disease component	Grant name	Grant end date	Currency	Total program budget	Existing funding	Incremental amount for Board approval	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic commitment
1	Armenia	HIV/AIDS	ARM-MOH-H	30 Sept 2018	US\$	5,626,288	710,948	3,240,258	4,915,340	N/A	5,015,040	6.2 million
			ARM-MEA-H	30 Sept 2018	US\$		0	1,675,082				
2	Azerbaijan	HIV/AIDS	AZE-H-MOH	30 June 2018	US\$	9,887,685	3,604,730	6,282,955	6,282,955	N/A	0	23.6 million
3	Belarus	HIV/AIDS	BLR-H-RSPCMT	31 Dec 2018	US\$	13,727,239	1,744,481	11,982,758	11,982,758	N/A	191,393	51.8 million
4	Belarus	TB	BLR-T-RSPCMT	31 Dec 2018	US\$	12,325,452	452,141	11,873,311	11,873,311	N/A	0	189.9 million
5	Benin	HIV/AIDS	BEN-H-BENPNLS	31 Dec 2017	€	28,641,072	21,500,531	0	4,860,581	N/A	0	7.23 million
			BEN-H-PlanBen	31 Dec 2017	€		2,279,960	4,860,581				
6	Benin	Malaria	BEN-M-PNLP	31 Dec 2017	€	31,541,017	7,904,770	23,636,247	23,636,247	8,372,774	0	6.72 million
7	Benin	TB	BEN-T-PNTUB	31 Dec 2017	€	5,988,747	1,369,346	4,619,401	4,619,401	398,982	0	1.36 million

8	Côte d'Ivoire*	Malaria	CIV-M-SCI	30 Dec 2017	€	12,999,177	8,899,472	4,099,706	4,099,706	N/A	19,532,595	65,916,636
9	Dominican Republic	TB	DOM-T-MSPAS	31 Dec 2018	US\$	8,373,610	608,585	7,765,025	7,765,025	N/A	0	67.1 million
10	El Salvador	TB	SLV-T-MOH	31 Dec 2018	US\$	9,950,916	150,000	9,800,916	9,800,916	N/A	0	24,456,238
11	Gabon	TB	GAB-T-MSPS	31 Dec 2018	€	3,630,386	0	3,630,386	3,630,386	N/A	0	10.5 million
12	Gambia	TB	GMB-T-NLTP	31 Dec 2017	US\$	7,989,687	1,343,987	6,645,700	6,645,700	352,000	0	356,990
13	Jamaica	HIV/AIDS	JAM-H-MOH	31 Dec 2018	US\$	15,242,178	323,560	14,918,618	14,918,618	N/A	0	53.6 million
14	Paraguay	TB	PRY-T-AVA	31 Dec 2018	US\$	5,988,073	425,056	5,563,017	5,563,017	N/A	0	15.7 million
15	Tajikistan	TB	TJK-T-HOPE	31 Dec 2017	US\$	17,966,668	4,677,082	8,622,891	13,289,586	N/A	0	16,006,534
			TJK-T-RCTC	31 Dec 2017	US\$		0	4,666,695				
16	Timor-Leste	TB	TLS-708-Go4-T	31 Dec 2017	US\$	4,813,831	625,139	4,188,692	4,188,692	N/A	908,297	10.95 million
17	Timor-Leste	HIV/AIDS	TLS-H-MOH	31 Dec 2017	US\$	4,312,116	3,944,635	367,480	367,480	N/A	0	4,426,110
18	Viet Nam	Malaria	VNM-M-NIMPE	31 Dec 2017	US\$	15,249,222	2,769,522	12,479,700	12,479,700	4,797,180	13,547,023	12.7 million

Table 1b: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Regional Applicant)

<b>N</b>	<b>Applicant</b>	<b>Disease Component</b>	<b>Currency</b>	<b>Grant name</b>	<b>Grant end date</b>	<b>Recommended budget</b>	<b>Total program budget</b>	<b>Existing funding</b>	<b>Incremental amount for Board approval</b>	<b>Recommended total incremental funding</b>	<b>Unfunded Quality Demand</b>
1	ICW Latina	HIV/AIDS	US\$	QRA-H-HIVOS	31 Dec 2018	4,330,296	4,330,296	0	4,330,296	4,330,296	0

Table 1c: Secretariat's Funding Recommendation on Additional Funding for Zimbabwe HIV Program

<b>Applicant</b>	<b>Grant Name</b>	<b>Currency</b>	<b>Approved Grant Budget</b>	<b>Revised Budget for Board Approval</b>	<b>Source of Funding</b>	<b>Incremental Funding Already Approved</b>	<b>Additional Incremental Funding for Board Approval</b>	<b>Revised Unfunded Quality Demand</b>
Zimbabwe	ZIM-H-UNDP	US\$	437,272,910	468,705,052	Incentive funding	126,053,783	25,274,085	127,621,036
					CIFF		6,160,057	

Table 2: Reinvestment of Within-Allocation Efficiencies for Previously-Approved Programs

<b>Applicant</b>	<b>Grant Name</b>	<b>Currency</b>	<b>Approved Grant Budget</b>	<b>Revised Budget for Board Approval</b>	<b>Existing Funding</b>	<b>Revised Existing Funding</b>	<b>Incremental Funding Already Approved</b>	<b>Additional Incremental Funding for Board Approval</b>	<b>Revised Unfunded Quality Demand</b>
Bangladesh <sup>1</sup>	BGD-M-BRAC	US\$	9,607,092	9,800,254	113,476	228,972	9,493,616	77,666	17,213,518
	BGD-M-NMCP	US\$	15,744,966	15,883,897	3,415,293	3,471,219	12,329,673	83,005	
Côte d'Ivoire	CIV-M-MOH	€	77,924,323	82,496,017	20,231,712	24,056,646	57,692,611	746,760	19,532,595

<sup>1</sup> The GAC recommends that the Board approve an increase to the budget amount of the Bangladesh malaria grants BAN-M-NMCP and BAN-M-BRAC. The additional amount requested is within the allocation and represents reinvestment of undisbursed and unused cash funds from round 10 grants that were not included in the total budget when the Board approved an incremental amount for the Bangladesh malaria grants on 30 June 2015 (GF/B33/EDP05). The CCM requests to reinvest this amount in unfunded quality demand, in line with the current program and TRP recommendations.